{"id":"48c7fbb5-da1d-4d8f-8891-16287b8388df","kind":"news","code":"48c7fbb5-da1d-4d8f-8891-16287b8388df","name":"iRegene raises RMB 260 million in Series C+ financing","nameBasis":"translated-title","summary":"On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.","description":"","country":null,"category":null,"originalName":"睿健医药完成C+融资，金额2.60亿人民币","eventDate":"2026-07-02T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T17:18:19.314Z","englishUpdatedAt":"2026-10-20T18:21:37.336Z","reviewedAt":"2026-10-20T18:21:37.336Z","snapshotAt":"2026-10-20T18:19:32.670Z","sourceHash":"952c547ad5eb57bf8d1dbe53be1cab5e2540393b32284532c5147f6372db89f6","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"originalText":"2026年7月2日，据烯牛数据报道，睿健医药完成C+融资，金额2.60亿人民币。投资方为成都科创投领投，中信建投资本、锡创投、鼎泰星、新基业、弘毅资本、元希海河（天津）生物医药产业基金合伙企业（有限合伙）跟投。该公司为化学诱导细胞治疗药物研发商。","sources":[],"related":[{"id":"7ca99c03-1fc1-4b26-8760-e932c8a325a8","kind":"institutions","code":"UB-I6579","name":"Chengdu Ke Venture Capital","nameBasis":"transliterated","summary":"Chengdu Ke Venture Capital is a domestic state-capital-backed investment guidance fund supporting technology companies through equity investment.","description":"Chengdu Ke Venture Capital is a domestic state-capital-backed investment guidance fund supporting technology companies through equity investment.","country":null,"category":null,"originalName":"成都科创投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:32:23.042Z","englishUpdatedAt":"2026-10-15T17:35:39.279Z","reviewedAt":"2026-10-15T17:35:39.279Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"cf254128ac493c10c818a2dd911576d872da8b629dce71fcc9926ae8ba5b6185","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/chengdu-ke-venture-capital"},{"id":"8e439b56-d2b5-486a-b3e0-bbecac857ff3","kind":"institutions","code":"UB-I8732","name":"Dingtaixing","nameBasis":"transliterated","summary":"Dingtaixing, an investment firm.","description":"Dingtaixing, an investment firm.","country":null,"category":null,"originalName":"鼎泰星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:28:23.403Z","englishUpdatedAt":"2026-10-15T17:35:39.375Z","reviewedAt":"2026-10-15T17:35:39.375Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"29de96700353caa2afe29381e2b137aee4920dd2a59beacbbe7e492459770d3e","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/dingtaixing"},{"id":"b8e1f19c-ef9f-4d5d-9c26-b2181ea3de76","kind":"institutions","code":"UB-I8645","name":"Hongyi Capital","nameBasis":"transliterated","summary":"Hongyi Capital, a private equity investment firm focused on healthcare.","description":"Hongyi Capital, a private equity investment firm focused on healthcare.","country":null,"category":null,"originalName":"弘毅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:28:22.433Z","englishUpdatedAt":"2026-10-15T17:35:39.635Z","reviewedAt":"2026-10-15T17:35:39.635Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ffd349b8aa041f772b04d9aa27561d787dd573f963995912d986b4fab47492b7","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/UB-I8645"},{"id":"00f10870-e66a-4d71-84c2-be1982e0db3c","kind":"institutions","code":"UB-I263","name":"Xi Venture Capital","nameBasis":"transliterated","summary":"A Wuxi municipal state-owned venture capital platform focused on local technology and industrial upgrading investments.","description":"A Wuxi municipal state-owned venture capital platform focused on local technology and industrial upgrading investments.","country":null,"category":null,"originalName":"锡创投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:18:21.614Z","englishUpdatedAt":"2026-10-15T21:17:22.004Z","reviewedAt":"2026-10-15T21:17:22.004Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"61b79f83f7879052cd3ec3027716d72ce2e057e8a20d71058e3dff9af86827c1","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/xi-venture-capital"},{"id":"46595315-f644-44b6-9534-8900f0ede36e","kind":"institutions","code":"UB-I8715","name":"Xinjiye","nameBasis":"transliterated","summary":"Xinjiye, an investment firm.","description":"Xinjiye, an investment firm.","country":null,"category":null,"originalName":"新基业","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-19T13:00:18.157Z","englishUpdatedAt":"2026-10-20T18:26:50.040Z","reviewedAt":"2026-10-20T18:26:50.040Z","snapshotAt":"2026-10-20T18:10:00.657Z","sourceHash":"ada34393996bfb6656cb2769342a1998fa588945f0a27571bae0aba92a05fb8f","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/xinjiye"},{"id":"f5c04936-20ae-42c6-8077-87ffb0ebcc32","kind":"institutions","code":"UB-I8618","name":"Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership)","nameBasis":"transliterated","summary":"Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), an industry investment fund focused on healthcare.","description":"Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), an industry investment fund focused on healthcare.","country":null,"category":null,"originalName":"元希海河（天津）生物医药产业基金合伙企业（有限合伙）","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:28:22.214Z","englishUpdatedAt":"2026-10-15T21:43:23.735Z","reviewedAt":"2026-10-15T21:43:23.735Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"6b4a436601e5f21936636a1b9dd36c156c38ea4c4499c30a063663c41cc4d0a8","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/yuanxihaihe-tianjin-biotechnology-pharmaceutical-industry-fund-partnership-limited-partnership"},{"id":"4c0829a6-b49d-4634-ae6b-10246749afbe","kind":"institutions","code":"UB-I1502","name":"Zhongxinjian Investment Ben","nameBasis":"transliterated","summary":"Private equity investment platform under CSC Financial.","description":"Private equity investment platform under CSC Financial.","country":null,"category":null,"originalName":"中信建投资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:04:28.309Z","englishUpdatedAt":"2026-10-15T20:27:18.706Z","reviewedAt":"2026-10-15T20:27:18.706Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"f872250e85db83bedc79f7520b140b3e333bd36cb7a26d3bbfdc57aa8222ee97","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/zhongxinjian-investment-ben"},{"id":"c6f40f74-5248-4720-8404-fd1e03022e90","kind":"companies","code":"UB-C5987","name":"iRegene","nameBasis":"source-english","summary":"AI and chemically induced cell drug research and development.","description":"","country":"China","category":null,"originalName":"睿健医药","eventDate":null,"website":"https://www.iregene.com/","sourceUpdatedAt":"2026-10-08T00:00:00.000Z","englishUpdatedAt":"2026-10-20T18:26:36.154Z","reviewedAt":"2026-10-20T18:26:36.154Z","snapshotAt":"2026-10-20T18:05:01.520Z","sourceHash":"4f1558709e5410f70940856de858bdad558b4dea9749771117809729b847f483","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/companies/UB-C5987"}],"path":"/news/48c7fbb5-da1d-4d8f-8891-16287b8388df","structured":{"city":null,"country":null,"location":null,"role":null,"category":null,"company":{"name":"iRegene","path":"/companies/UB-C5987"}},"canonical":"https://uniquebase.ai/news/48c7fbb5-da1d-4d8f-8891-16287b8388df"}